NEW YORK (GenomeWeb News) – Mizuho Securities USA has initiated coverage of Exact Sciences with a Buy rating and a $13 price target.

The Madison, Wis.-based firm is developing the Cologuard test, a stool-based DNA test for colorectal cancer screening. Mizuho analyst Peter Lawson said in a note that there is a "large untapped revenue opportunity available to Cologuard of over $1.2 billion in the US with limited competition."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.